Article

APOBEC3G expression marks a TMB-high, T cell-inflamed tumor state and is associated with response to immune checkpoint blockade in multiple cancer cohorts

2026-07-13

Abstract excerpt

Immune checkpoint therapies have transformed clinical practice; however, reliable biomarkers to predict response remain limited. Tumor mutational burden (TMB) has emerged as an important biomarker because it is thought to reflect neoantigen load, yet its predictive utility has been inconsistent. This limitation may partly arise because TMB primarily captures tumor-intrinsic immunogenicity, which is heterogeneous a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3a1f5958-8488-55d4-9499-e766c8a52771
DOI: 10.64898/2026.07.08.737369

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

APOBEC3G expression marks a TMB-high, T cell-inflamed tumor state and is associated with response to immune checkpoint blockade in multiple cancer cohortsDOI 10.64898/2026.07.08.737369Read

APOBEC3-driven neoantigen-rich cancers co-opt 1q23.3 amplification for tumor-intrinsic immune cloakingSemantic proximity Read

Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer typesSemantic proximity Read

Landscape of tumor-infiltrating T cell repertoire of human cancers.Semantic proximity Read

Identification and characterization of neoantigen-reactive CD8+ T cells following checkpoint blockade therapy in a pan-cancer settingSemantic proximity Read

Is tumor mutational burden predictive of response to immunotherapy?Semantic proximity Read

The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives.Semantic proximity Read

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.Semantic proximity Read

Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockadeSemantic proximity Read

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current EvidenceSemantic proximity Read

Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapySemantic proximity Read

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.Semantic proximity Read

Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burdenSemantic proximity Read